Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.53
NVS's Cash to Debt is ranked higher than
56% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. NVS: 0.53 )
NVS' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.53

Equity to Asset 0.57
NVS's Equity to Asset is ranked higher than
65% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. NVS: 0.57 )
NVS' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.65
Current: 0.57

0.51
0.65
Interest Coverage 15.97
NVS's Interest Coverage is ranked higher than
59% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 97.33 vs. NVS: 15.97 )
NVS' s 10-Year Interest Coverage Range
Min: 13.56   Max: 30.91
Current: 15.97

13.56
30.91
F-Score: 7
Z-Score: 3.34
M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 19.04
NVS's Operating margin (%) is ranked higher than
90% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. NVS: 19.04 )
NVS' s 10-Year Operating margin (%) Range
Min: 17.81   Max: 24.34
Current: 19.04

17.81
24.34
Net-margin (%) 17.61
NVS's Net-margin (%) is ranked higher than
91% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.37 vs. NVS: 17.61 )
NVS' s 10-Year Net-margin (%) Range
Min: 15.35   Max: 31.38
Current: 17.61

15.35
31.38
ROE (%) 15.05
NVS's ROE (%) is ranked higher than
88% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. NVS: 15.05 )
NVS' s 10-Year ROE (%) Range
Min: 12.66   Max: 24.94
Current: 15.05

12.66
24.94
ROA (%) 8.60
NVS's ROA (%) is ranked higher than
87% of the 816 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. NVS: 8.60 )
NVS' s 10-Year ROA (%) Range
Min: 7.25   Max: 15.7
Current: 8.6

7.25
15.7
ROC (Joel Greenblatt) (%) 53.52
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. NVS: 53.52 )
NVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 38.01   Max: 73.12
Current: 53.52

38.01
73.12
Revenue Growth (%) -0.20
NVS's Revenue Growth (%) is ranked higher than
61% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. NVS: -0.20 )
NVS' s 10-Year Revenue Growth (%) Range
Min: -0.2   Max: 74.8
Current: -0.2

-0.2
74.8
EBITDA Growth (%) 4.80
NVS's EBITDA Growth (%) is ranked higher than
71% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. NVS: 4.80 )
NVS' s 10-Year EBITDA Growth (%) Range
Min: -6.3   Max: 84.5
Current: 4.8

-6.3
84.5
EPS Growth (%) -6.40
NVS's EPS Growth (%) is ranked higher than
67% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. NVS: -6.40 )
NVS' s 10-Year EPS Growth (%) Range
Min: -6.4   Max: 83.6
Current: -6.4

-6.4
83.6
» NVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NVS Guru Trades in Q3 2013

RS Investment Management 55,920 sh (New)
Jim Simons 424,200 sh (New)
Steven Cohen 4,624 sh (New)
Sarah Ketterer 71,794 sh (+21.87%)
Lee Ainslie 804,099 sh (+8.41%)
Ken Fisher 5,725,853 sh (+1.75%)
Manning & Napier Advisors, Inc 370,557 sh (+1.19%)
John Hussman 221,200 sh (+1.05%)
John Buckingham 83,563 sh (+0.12%)
Mario Gabelli 10,840 sh (unchged)
Pioneer Investments 85,400 sh (unchged)
Jean-Marie Eveillard 13,060 sh (unchged)
Chris Davis Sold Out
Tweedy Browne 295,290 sh (-0.27%)
HOTCHKIS & WILEY 2,126,326 sh (-0.53%)
Dodge & Cox 46,862,302 sh (-0.62%)
PRIMECAP Management 26,850,538 sh (-0.82%)
Murray Stahl 29,300 sh (-1.01%)
Irving Kahn 29,368 sh (-3.29%)
Bill Frels 3,824 sh (-10.92%)
» More
Q4 2013

NVS Guru Trades in Q4 2013

Sarah Ketterer 281,741 sh (+292.43%)
Steven Cohen 8,530 sh (+84.47%)
Jim Simons 659,298 sh (+55.42%)
RS Investment Management 80,049 sh (+43.15%)
John Buckingham 84,596 sh (+1.24%)
Ken Fisher 5,787,120 sh (+1.07%)
Mario Gabelli 10,840 sh (unchged)
Jean-Marie Eveillard 13,060 sh (unchged)
John Hussman 221,200 sh (unchged)
Pioneer Investments 85,400 sh (unchged)
Murray Stahl 29,300 sh (unchged)
PRIMECAP Management 26,720,705 sh (-0.48%)
Dodge & Cox 46,485,352 sh (-0.8%)
Tweedy Browne 292,340 sh (-1%)
HOTCHKIS & WILEY 2,077,223 sh (-2.31%)
Manning & Napier Advisors, Inc 359,927 sh (-2.87%)
Irving Kahn 27,368 sh (-6.81%)
Bill Frels 3,555 sh (-7.03%)
Lee Ainslie 267,321 sh (-66.76%)
» More
Q1 2014

NVS Guru Trades in Q1 2014

Steven Cohen 12,821 sh (+50.3%)
Lee Ainslie 351,580 sh (+31.52%)
Sarah Ketterer 327,343 sh (+16.19%)
Bill Frels 4,105 sh (+15.47%)
HOTCHKIS & WILEY 2,302,956 sh (+10.87%)
Irving Kahn 28,068 sh (+2.56%)
Ken Fisher 5,889,287 sh (+1.77%)
John Buckingham 85,174 sh (+0.68%)
Murray Stahl 29,358 sh (+0.2%)
Jean-Marie Eveillard 13,060 sh (unchged)
John Hussman 221,200 sh (unchged)
Pioneer Investments 85,400 sh (unchged)
Dodge & Cox 46,441,169 sh (-0.1%)
Tweedy Browne 291,500 sh (-0.29%)
Mario Gabelli 10,740 sh (-0.92%)
RS Investment Management 76,544 sh (-4.38%)
PRIMECAP Management 24,014,586 sh (-10.13%)
Manning & Napier Advisors, Inc 314,309 sh (-12.67%)
Jim Simons 96,000 sh (-85.44%)
» More
Q2 2014

NVS Guru Trades in Q2 2014

Louis Moore Bacon 180,000 sh (New)
Dodge & Cox 51,102,219 sh (+10.04%)
Manning & Napier Advisors, Inc 332,704 sh (+5.85%)
Ken Fisher 5,969,963 sh (+1.37%)
Pioneer Investments 86,323 sh (+1.08%)
RS Investment Management 76,745 sh (+0.26%)
Murray Stahl 29,425 sh (+0.23%)
Jean-Marie Eveillard 13,060 sh (unchged)
Bill Frels 4,105 sh (unchged)
Steven Cohen 69,500 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 23,846,236 sh (-0.7%)
Tweedy Browne 288,825 sh (-0.92%)
John Buckingham 83,941 sh (-1.45%)
Sarah Ketterer 320,852 sh (-1.98%)
John Hussman 214,000 sh (-3.25%)
Mario Gabelli 10,240 sh (-4.66%)
Irving Kahn 26,368 sh (-6.06%)
HOTCHKIS & WILEY 649,519 sh (-71.8%)
Jim Simons 14,000 sh (-85.42%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2014-06-30 Reduce -71.8%0.52%$82.51 - $90.98 $ 91.955%649519
Lee Ainslie 2014-06-30 Sold Out 0.42%$82.51 - $90.98 $ 91.955%0
Dodge & Cox 2014-06-30 Add 10.04%0.4%$82.51 - $90.98 $ 91.955%51102219
PRIMECAP Management 2014-03-31 Reduce -10.13%0.26%$78.2 - $83.82 $ 91.9513%24014586
Lee Ainslie 2014-03-31 Add 31.52%0.1%$78.2 - $83.82 $ 91.9513%351580
Lee Ainslie 2013-12-31 Reduce -66.76%0.56%$72.96 - $80.39 $ 91.9519%267321
Chris Davis 2013-09-30 Sold Out 0.01%$70.66 - $77.08 $ 91.9524%0
John Hussman 2013-06-30 Reduce -47.49%0.52%$68.42 - $75.5 $ 91.9527%218900
Vanguard Health Care Fund 2013-06-30 Sold Out 0.2%$68.42 - $75.5 $ 91.9527%0
Lee Ainslie 2013-06-30 Add 39.5%0.2%$68.42 - $75.5 $ 91.9527%741689
Vanguard Health Care Fund 2013-03-31 Reduce -85.39%0.71%$63.3 - $71.32 $ 91.9536%726200
Lee Ainslie 2013-03-31 New Buy0.49%$63.3 - $71.32 $ 91.9536%531689
Irving Kahn 2013-03-31 Reduce -21.03%0.1%$63.3 - $71.32 $ 91.9536%33456
Dodge & Cox 2012-12-31 Add 2.65%0.11%$58.97 - $63.96 $ 91.9549%48438459
Ken Fisher 2012-09-30 New Buy0.86%$55.24 - $61.51 $ 91.9557%5086362
Dodge & Cox 2012-09-30 Add 3.23%0.12%$55.24 - $61.51 $ 91.9557%47187759
Michael Price 2012-03-31 Sold Out 1.3%$53.31 - $58.33 $ 91.9576%0
John Hussman 2012-03-31 Reduce -22.44%0.14%$53.31 - $58.33 $ 91.9576%515000
Ken Fisher 2012-03-31 Sold Out 0.13%$53.31 - $58.33 $ 91.9576%0
Mario Gabelli 2012-03-31 Reduce -37.42%$53.31 - $58.33 $ 91.9576%11740
Chris Davis 2011-12-31 New Buy$51.65 - $58.86 $ 91.9565%33400
HOTCHKIS & WILEY 2011-09-30 Reduce -27.02%0.33%$53.73 - $62.82 $ 91.9558%2473003
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Novartis AG

Top Guru-Bought European Stocks of the Third Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were bought by the highest number of gurus. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.50
NVS's P/E(ttm) is ranked higher than
86% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.00 vs. NVS: 22.50 )
NVS' s 10-Year P/E(ttm) Range
Min: 7.96   Max: 23.27
Current: 22.5

7.96
23.27
P/B 3.10
NVS's P/B is ranked higher than
72% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. NVS: 3.10 )
NVS' s 10-Year P/B Range
Min: 1.71   Max: 4.07
Current: 3.1

1.71
4.07
P/S 3.90
NVS's P/S is ranked higher than
69% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.73 vs. NVS: 3.90 )
NVS' s 10-Year P/S Range
Min: 1.93   Max: 4.56
Current: 3.9

1.93
4.56
PFCF 26.00
NVS's PFCF is ranked higher than
93% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVS: 26.00 )
NVS' s 10-Year PFCF Range
Min: 7.12   Max: 25.96
Current: 26

7.12
25.96
EV-to-EBIT 20.68
NVS's EV-to-EBIT is ranked higher than
84% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. NVS: 20.68 )
NVS' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 21.5
Current: 20.68

9.1
21.5
PEG 5.26
NVS's PEG is ranked higher than
85% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVS: 5.26 )
NVS' s 10-Year PEG Range
Min: 0.29   Max: 83.26
Current: 5.26

0.29
83.26
Shiller P/E 22.30
NVS's Shiller P/E is ranked higher than
90% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 95.10 vs. NVS: 22.30 )
NVS' s 10-Year Shiller P/E Range
Min: 9.38   Max: 23.79
Current: 22.3

9.38
23.79
Current Ratio 1.38
NVS's Current Ratio is ranked higher than
55% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. NVS: 1.38 )
NVS' s 10-Year Current Ratio Range
Min: 0.9   Max: 2.83
Current: 1.38

0.9
2.83
Quick Ratio 1.14
NVS's Quick Ratio is ranked higher than
57% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. NVS: 1.14 )
NVS' s 10-Year Quick Ratio Range
Min: 0.66   Max: 2.48
Current: 1.14

0.66
2.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.90
NVS's Dividend Yield is ranked higher than
96% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. NVS: 2.90 )
NVS' s 10-Year Dividend Yield Range
Min: 1.52   Max: 4.89
Current: 2.9

1.52
4.89
Dividend Payout 0.66
NVS's Dividend Payout is ranked higher than
74% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. NVS: 0.66 )
NVS' s 10-Year Dividend Payout Range
Min: 1.06   Max: 2.65
Current: 0.66

1.06
2.65
Dividend growth (3y) 6.10
NVS's Dividend growth (3y) is ranked higher than
71% of the 360 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. NVS: 6.10 )
NVS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 17.7
Current: 6.1

0
17.7
Yield on cost (5-Year) 4.23
NVS's Yield on cost (5-Year) is ranked higher than
83% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. NVS: 4.23 )
NVS' s 10-Year Yield on cost (5-Year) Range
Min: 2.14   Max: 6.89
Current: 4.23

2.14
6.89
Share Buyback Rate -2.70
NVS's Share Buyback Rate is ranked higher than
72% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.20 vs. NVS: -2.70 )
NVS' s 10-Year Share Buyback Rate Range
Min: 42.5   Max: -2.7
Current: -2.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.81
NVS's Price/Tangible Book is ranked higher than
56% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.86 vs. NVS: 12.81 )
NVS' s 10-Year Price/Tangible Book Range
Min: 0.16   Max: 94.26
Current: 12.81

0.16
94.26
Price/DCF (Projected) 1.44
NVS's Price/DCF (Projected) is ranked higher than
91% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. NVS: 1.44 )
NVS' s 10-Year Price/DCF (Projected) Range
Min: 0.67   Max: 1.46
Current: 1.44

0.67
1.46
Price/Median PS Value 1.24
NVS's Price/Median PS Value is ranked higher than
70% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. NVS: 1.24 )
NVS' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 3.21
Current: 1.24

0.67
3.21
Price/Graham Number 3.50
NVS's Price/Graham Number is ranked higher than
72% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.75 vs. NVS: 3.50 )
NVS' s 10-Year Price/Graham Number Range
Min: 0.07   Max: 77.84
Current: 3.5

0.07
77.84
Earnings Yield (Greenblatt) 4.80
NVS's Earnings Yield (Greenblatt) is ranked higher than
83% of the 794 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. NVS: 4.80 )
NVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.6   Max: 11
Current: 4.8

4.6
11
Forward Rate of Return (Yacktman) 4.42
NVS's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. NVS: 4.42 )
NVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.9   Max: 68.4
Current: 4.42

4.9
68.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, ABT » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NVSEF.USA, NOT.Germany, NOTA.Germany, NVS N.Mexico, NOVNEE.Switzerland
Novartis AG was incorporated on February 29, 1996 under the laws of Switzerland. On December 20, 1996, the Company's predecessor companies, Ciba-Geigy and Sandoz, merged into this new entity, creating Novartis. The Company provides healthcare solutions that address the evolving needs of patients and societies worldwide with a portfolio that includes innovative medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products. The Group's businesses are divided on a worldwide basis into the following four operating divisions: Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health. Pharmaceuticals Division researches, develops, manufactures, distributes and sells branded prescription medicines in the following therapeutic areas: Cardiovascular and Metabolism; Oncology; Neuroscience and Ophthalmics; Respiratory; Immunology and Infectious Diseases; and Other. Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Its Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances. It has activities in Retail Generics, Anti-Infectives and Biopharmaceuticals. Consumer Health Division consists of three business units: OTC, Animal Health and CIBA Vision. Each has its own research, development, manufacturing, distribution and selling capabilities. Each has manufacturing, distribution and selling capabilities. In global pharmaceutical market it competes against other international corporations which sell branded prescription pharmaceutical products. Novartis generally sells its prescription drugs mainly to wholesale and retail drug distributors, hospitals, clinics, government agencies and managed healthcare providers. The international pharmaceutical industry is regulated. Regulatory authorities around the world administer numerous laws and regulations regarding the testing, approval, manufacturing, importing, labeling and marketing of drugs, and also review the safety and efficacy of pharmaceutical products.
» More Articles for NYSE:NVS

Headlines

Articles On GuruFocus.com
Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
International Securities For A Diversified Income Portfolio Sep 23 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
A Strong Candidate for Investor´s Portfolios Aug 12 2014 
Novartis: Ten Years of Solid ROE Jul 31 2014 

More From Our Partners
Novartis' (NVS) CEO Joe Jimenez on Q3 2014 Results - Earnings Call Transcript Oct 28 2014 - SEEKINGALPHA

More From Other Websites
Veeva Systems Flies High On Cloud For Life Sciences Oct 30 2014
[video]Novartis, Taiwan Semi Tough to Beat Says Aberdeen Fund Manager Oct 30 2014
Did Novartis Make a Ham-Handed Move to Promote an Antibiotic for Pigs? Oct 30 2014
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View Oct 29 2014
Novartis Oct 28 2014
NOVARTIS AG (NVS) Earnings Report: Q3 2014 Conference Call Transcript Oct 28 2014
Novartis Q3 earnings boosted by new drugs Oct 28 2014
Swiss drug maker Novartis posts strong profit Oct 28 2014
Swiss drug maker Novartis posts strong profit Oct 28 2014
Swiss drug maker Novartis posts 3Q profit Oct 28 2014
Novartis' precision M&A plan: CEO Oct 28 2014
Novartis CEO on big pharma pipeline Oct 28 2014
Novartis results top forecasts as new products gain momentum Oct 28 2014
[$$] Novartis Up On Productivity Gains Oct 28 2014
Novartis sees new heart failure drug as 'multi-blockbuster' Oct 28 2014
Novartis Third-Quarter Profit Climbs on New Products Oct 28 2014
Novartis delivered solid sales growth with strong margin expansion and major innovation in the third... Oct 28 2014
Will Novartis (NVS) Disappoint in Q3 Earnings Season? Oct 27 2014
Novartis selling flu vaccine unit to CSL for $275M Oct 27 2014
Novartis selling flu vaccine unit to CSL for $275M Oct 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK